Top

Published in:

01-04-2015 | Breast Oncology

Determining the Role of Gene Expression Assays in Local Therapy for Breast Cancer: First Steps with a Positive Impression

Author: Mackenzie Daly, MD

Published in: Annals of Surgical Oncology | Issue 4/2015

Excerpt

Determining when post-mastectomy radiation therapy (PMRT) should be utilized in breast cancer patients with T1 or T2 tumors and 1–3 positive lymph nodes is an area of uncertainty. In this patient population, balancing the benefits of improved local control and overall survival with the long-term complications of therapeutic radiation relies heavily on the ‘art of medicine’.1,2 The paper submitted by Dr. Jegadeesh and colleagues published in this issue of Annals of Surgical Oncology suggests that the 21-gene recurrence score assay may be a tool to optimize local therapy for breast cancer patients. Furthermore, the authors offer a novel perspective on utilizing the recurrence score for clinical decision making.3 …

Clarke M, Collins R, Darby S, et al. Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomized trials. Lancet. 2005;366(9503):2087–16.

McGale P, Taylor C, Correa C, et al. Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: meta-analysis of individual patient data for 8135 women in 22 randomized trials. Lancet. 2014:383(9935):2127–35.CrossRefPubMed

Jegadeesh N, Kim S, Oprea G, et al. The 21-gene recurrence score and locoregional recurrence in breast cancer patients. Ann Surg Oncol.

Overgaard M, Hansen PS, Overgaard J, et al. Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy. Danish Breast Cancer Cooperative Group 82b Trial. N Engl J Med. 1997;337(14):949–55.CrossRefPubMed

Overgaard M, Jensen MB, Overgaard J, et al. Postoperative radiotherapy in high-risk postmenopausal breast-cancer patients given adjuvant tamoxifen. Danish Breast Cancer Cooperative Group DBCG 82c Trial. Lancet. 1999;353(9165):1641–8.CrossRefPubMed

Recht A, Edge SB, Solin LJ, et al. Postmastectomy radiotherapy: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol. 2001;19(5):1539–69.PubMed

Wallgreen A, Bonbetti M, Gelber RD, et al. Risk factors for locoregional recurrence among breast cancer patients: results from International Breast Study Group Trials I through VII. J Clin Oncol. 2003;21(7):1205–13.CrossRef

Cheng S, Horng C, Clarke J, et al. Prognostic index score and clinical prediction model of local regional recurrence after mastectomy in breast cancer patients. Int J Radiat Oncol Biol Phys. 2006;64(5):1401–9.CrossRefPubMed

Fisher B, Dignam J, Tan-Chiu E, et al. Prognosis and treatment of patients with breast tumors of one centimeter or less and negative axillary nodes. J Natl Cancer Inst. 2001;93(2):112–20.CrossRefPubMed

10.

Paik S, Shak S, Tang G, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med. 2004;351(27):2817–26.CrossRefPubMed

11.

Albain K, Barlo W, Shak S, et al. Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomized trial. Lancet. 2010;11(1):55–65.CrossRefPubMedCentralPubMed

12.

Mamounas E, Tang G, Fisher B. Association between the 21-gene recurrence score assay and risk of locoregional recurrence in node-negative, estrogen receptor-positive breast cancer: results from NSABP B-14 and BSABP B-20. J Clin Oncol. 2010;28(10):1677–83.CrossRefPubMedCentralPubMed

13.

Solin LJ, Gray R, Goldstein LJ, et al. Prognostic value of biologic subtype and the 21-gene recurrence score relative to local recurrence after breast conservation treatment with radiation for early stage breast carcinoma: results from the Eastern Cooperative Oncology Group E2197 study. Breast Cancer Res Treat. 2012;134(2):683–92.CrossRefPubMedCentralPubMed

14.

Fisher B, Costantino J, Redmond C, et al. A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors. N Engl J Med. 1989;320(8):479–84.CrossRefPubMed

15.

Fisher B, Dignam J, Wolmark N, et al. Tamoxifen and chemotherapy for lymph node-negative, estrogen receptor-positive breast cancer. J Natl Cancer Inst. 1997;89(2):1673–82.CrossRefPubMed

Title: Determining the Role of Gene Expression Assays in Local Therapy for Breast Cancer: First Steps with a Positive Impression
Author: Mackenzie Daly, MD
Publication date: 01-04-2015
Publisher: Springer US
Published in: Annals of Surgical Oncology / Issue 4/2015
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI: https://doi.org/10.1245/s10434-014-4253-x

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Determining the Role of Gene Expression Assays in Local Therapy for Breast Cancer: First Steps with a Positive Impression

Excerpt

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 4/2015

Development and Assessment of Memorial Sloan Kettering Cancer Center’s Surgical Secondary Events Grading System

LINE-1 Methylation Level and Patient Prognosis in a Database of 208 Hepatocellular Carcinomas

Impact of Multifocal or Multicentric Disease on Surgery and Locoregional, Distant and Overall Survival of 6,134 Breast Cancer Patients Treated With Neoadjuvant Chemotherapy

Abdominal Desmoplastic Small Round Cell Tumor: Multimodal Treatment Combining Chemotherapy, Surgery, and Radiotherapy is the Best Option

CaPTHUS Scoring Model in Primary Hyperparathyroidism: Can It Eliminate the Need for ioPTH Testing?

Applicability of the ACOSOG Z0011 Criteria in Women with High-Risk Node-Positive Breast Cancer Undergoing Breast Conserving Surgery